Cargando…

Immunogenicity, safety and reactogenicity of heterologous (third dose) booster vaccination with a full or fractional dose of two different COVID-19 vaccines: A phase 4, single-blind, randomized controlled trial in adults

In this phase 4 study we assessed boosting with fractional doses of heterologous COVID-19 vaccines in Brazilian adults primed with two doses of CoronaVac (Sinovac/Butantan, São Paulo, Brazil) at least 4 months previously. Participants received either full-dose of ChAdOx1-S (Group 1, n = 232), a half...

Descripción completa

Detalles Bibliográficos
Autores principales:	Costa Clemens, Sue Ann, Marchevsky, Natalie, Kelly, Sarah, Felle, Sally, Eldawi, Ahmed, Rajasingam, Rupetha, Mahmud, Rawan, Lambe, Teresa, Voysey, Merryn, Gonzalez, Isabela, Milan, Eveline Pipolo, Justino, Maria Cleonice, Bibi, Sagida, Aley, Parvinder, Clemens, Ralf, Pollard, Andrew J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2023
Materias:	Coronavirus
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10348030/ https://www.ncbi.nlm.nih.gov/pubmed/37438960 http://dx.doi.org/10.1080/21645515.2023.2233400

Ejemplares similares

Immunogenicity and reactogenicity of heterologous COVID-19 vaccination in pregnant women
por: Chayachinda, Chenchit, et al.
Publicado: (2023)

An exploratory analysis of the response to ChAdOx1 nCoV-19 (AZD1222) vaccine in males and females
por: Marchevsky, Natalie Gabrielle, et al.
Publicado: (2022)

Hesitancy, reactogenicity and immunogenicity of the mRNA and whole-virus inactivated Covid-19 vaccines in pediatric neuromuscular diseases
por: Yu, Michael Kwan Leung, et al.
Publicado: (2023)

Immunogenicity and reactogenicity of heterologous prime-boost vaccination with inactivated COVID-19 and ChAdOx1 nCoV-19 (AZD1222) vaccines, a quasi-experimental study
por: Tawinprai, Kriangkrai, et al.
Publicado: (2023)

Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002)
por: Flaxman, Amy, et al.
Publicado: (2021)

Bivalent second booster dose of the COVID-19 vaccine: Eligible populations’ reasons for receiving in Italy
por: Della Polla, Giorgia, et al.
Publicado: (2023)

Safety and immunogenicity of a heterologous booster with an RBD virus-like particle vaccine following two- or three-dose inactivated COVID-19 vaccine
por: Yong, Xiaolan, et al.
Publicado: (2023)

Comparison of antibody persistency through one year between one-dose and two-dose regimens of Ad5-nCoV vaccine for COVID-19
por: Feng, Jia-Lu, et al.
Publicado: (2023)

Side effects following first dose of COVID-19 vaccination in Ho Chi Minh City, Vietnam
por: Nguyen, Si Van, et al.
Publicado: (2023)

The association between adverse events of COVID-19 vaccination and anxiety and willingness to receive a booster dose
por: Chen, Liling, et al.
Publicado: (2023)

COVID-19 vaccine booster dose hesitancy among key groups: A cross-sectional study
por: Huang, Min, et al.
Publicado: (2023)

Progression of hemolysis in a patient with hereditary spherocytosis after the second dose of COVID-19 mRNA vaccine
por: Nomura, Jun, et al.
Publicado: (2023)

Persistence of immunogenicity, contributing factors of an immune response, and reactogenicities after a single dose of the ChAdOx1 (AZD1222) COVID-19 vaccine in the Thai population
por: Tawinprai, Kriangkrai, et al.
Publicado: (2022)

Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 lineages circulating in Brazil
por: Clemens, Sue Ann Costa, et al.
Publicado: (2021)

Homologous or heterologous immunization regimens against SARS-CoV-2 after two doses of inactivated COVID-19 vaccine: Comment
por: Mungmunpuntipantip, Rujitika, et al.
Publicado: (2023)

Three doses of an inactivation-based COVID-19 vaccine induces cross-neutralizing immunity against the SARS CoV-2 Omicron variant
por: Yu, Xiaoling, et al.
Publicado: (2022)

Neutralization of Omicron sublineages and Deltacron SARS-CoV-2 by three doses of BNT162b2 vaccine or BA.1 infection
por: Kurhade, Chaitanya, et al.
Publicado: (2022)

Real-life effectiveness of COVID-19 vaccine during the Omicron variant-dominant pandemic: how many booster doses do we need?
por: Sritipsukho, Paskorn, et al.
Publicado: (2023)

The Third dose of CoronVac vaccination induces broad and potent adaptive immune responses that recognize SARS-CoV-2 Delta and Omicron variants
por: Chen, Yuxin, et al.
Publicado: (2022)

Immunogenicity and reactogenicity after heterologous prime-boost vaccination with CoronaVac and ChAdox1 nCov-19 (AZD1222) vaccines
por: Cohen, Guy, et al.
Publicado: (2022)

Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study
por: Costa Clemens, Sue Ann, et al.
Publicado: (2022)

Immunogenicity and safety of single booster dose of KD-414 inactivated COVID-19 vaccine in adults: An open-label, single-center, non-randomized, controlled study in Japan
por: Terada-Hirashima, Junko, et al.
Publicado: (2023)

Effectiveness of a booster dose of COVID-19 vaccines during an outbreak of SARS-CoV-2 Omicron BA.2.2 in China: A case–control study
por: Zhang, Xiaqing, et al.
Publicado: (2023)

Effectiveness of homologous or heterologous immunization regimens against SARS-CoV-2 after two doses of inactivated COVID-19 vaccine: A systematic review and meta-analysis
por: Zhang, Xiaoyin, et al.
Publicado: (2023)

Assessing sex-differences and the effect of timing of vaccination on immunogenicity, reactogenicity and efficacy of vaccines in young children: study protocol for an individual participant data meta-analysis of randomised controlled trials
por: Voysey, Merryn, et al.
Publicado: (2016)

Heterologous boosting with third dose of coronavirus disease recombinant subunit vaccine increases neutralizing antibodies and T cell immunity against different severe acute respiratory syndrome coronavirus 2 variants
por: Zhao, Zhuxiang, et al.
Publicado: (2022)

Safety and reactogenicity of second booster doses for mRNA vaccines
por: Wilder-Smith, Annelies, et al.
Publicado: (2023)

Trajectory of COVID-19 vaccine hesitancy post-vaccination and public’s intention to take booster vaccines: A cross-sectional analysis
por: Salman, Muhammad, et al.
Publicado: (2023)

Correlates of uptake of COVID-19 vaccines and motivation to vaccinate among Malawian adults
por: Whitehead, Hannah S., et al.
Publicado: (2023)

Acceptability of the third dose of anti-SARS-CoV-2 vaccine co-administered with influenza vaccine: preliminary data in a sample of Italian HCWs
por: Stefanizzi, Pasquale, et al.
Publicado: (2021)

COVID-19 mass vaccination – an illustration of the impact of syringe choice on the effectiveness of mass vaccination campaigns
por: Mazet, Roseline, et al.
Publicado: (2022)

Tracking trends in COVID-19 vaccines based on 47 different vaccines: A bibliometric review
por: Tao, Zhongbin, et al.
Publicado: (2023)

Booster vaccination is required to elicit and maintain COVID-19 vaccine-induced immunity in SIV-infected macaques
por: Li, Pingchao, et al.
Publicado: (2023)

Single cell characteristics of patients with vaccine-related adverse reactions following inactivated COVID-19 vaccination
por: Jiang, Manling, et al.
Publicado: (2023)

Why is it necessary to improve COVID-19 vaccination coverage in older people? How to improve the vaccination coverage?
por: Zhu, Ke-Wei
Publicado: (2023)

Supporting healthcare workers in vaccination efforts
por: Ramot, Shira, et al.
Publicado: (2023)

A replication-competent smallpox vaccine LC16m8Δ-based COVID-19 vaccine
por: Sakamoto, Akihiko, et al.
Publicado: (2022)

“In general people aren’t excited about the vaccine…”: Frontline perspectives on COVID-19 vaccine hesitancy across Syria
por: Alhaffar, Mervat, et al.
Publicado: (2023)

The impact of the COVID-19 pandemic on vaccination uptake in the United States and strategies to recover and improve vaccination rates: A review
por: Cunniff, Luke, et al.
Publicado: (2023)

Evaluation of immunogenicity post two doses of inactivated SARS-CoV-2 vaccine, Covaxin after six months
por: Sahay, Rima R., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ete1cuhgfvks49k2nkf98kjmv8